Mn1 Overexpression Induces Acute Myeloid Leukemia in Mice and Predicts Atra Resistance in Patients with Aml.
From: Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
Blood
- Publish Date: Sep 2007
- ISSN: 0006-4971
- Volume: 110
- Issue: 5
- Pages: 1639-47
- Medium: Print
- Language: English
- Citation (JAMA): Heuser Michael, Argiropoulos Bob, Kuchenbauer Florian, et al. Mn1 Overexpression Induces Acute Myeloid Leukemia in Mice and Predicts Atra Resistance in Patients with Aml.. Blood Sep 2007;110:1639-47
Abstract
Overexpression of wild-type MN1 is a negative prognostic factor in patients with acute myeloid leukemia (AML) with normal cytogenetics. We evaluated whether MN1 plays a functional role in leukemogenesis. We demonstrate using retroviral gene transfer and bone marrow (BM) transplantation that MN1 overexpression rapidly induces lethal AML in mice. Insertional mutagenesis and chromosomal instability were ruled out as secondary aberrations. MN1 increased resistance to all-trans retinoic acid (ATRA)-induced cell-cycle arrest and differentiation by more than 3000-fold in vitro. The differentiation block could be released by fusion of a transcriptional activator (VP16) to MN1 without affecting the ability to immortalize BM cells, suggesting that MN1 blocks differentiation by transcriptional repression. We then evaluated whether MN1 expression levels in patients with AML (excluding M3-AML) correlated with resistance to ATRA treatment in elderly patients uniformly treated within treatment protocol AMLHD98-B. Strikingly, patients with low MN1 expression who received ATRA had a significantly prolonged event-free (P = .008) and overall (P = .04) survival compared with patients with either low MN1 expression and no ATRA, or high MN1 expression with or without ATRA. MN1 is a unique oncogene in hematopoiesis that both promotes proliferation/self-renewal and blocks differentiation, and may become useful as a predictive marker in AML treatment.
Mesh Headings (Keywords): Aged, Animals, Antineoplastic Agents, Bone Marrow Cells, Cell Cycle, Cell Differentiation, Cell Transformation, Viral, Chromosomal Instability, Disease-Free Survival, Drug Resistance, Neoplasm, Gene Expression Regulation, Leukemic, Hematopoiesis, Herpes Simplex Virus Protein Vmw65, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Mutagenesis, Insertional, Predictive Value of Tests, Recombinant Fusion Proteins, Repressor Proteins, Retroviridae, Risk Factors, Survival Rate, Transduction, Genetic, Tretinoin, Tumor Markers, Biological, Tumor Suppressor Proteins
Check for Full Text / PubMed Unique Identifier (PMID): 17494859
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.